RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells

Blood

Volumn 110, Issue 2, 2007, Pages 640-650

  Hattori, Hidenori ^a,b   Zhang, Xueqing ^c   Jia, Yonghui ^a,b   Subramanian, Kulandayan K ^a,b   Jo, Hakryul ^a,b   Loison, Fabien ^a,b   Newburger, Peter E ^c   Luo, Hongbo R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; RETINOIC ACID; SHORT HAIRPIN RNA; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME 2D3; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; METABOLIC REGULATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN DEGRADATION; RNA INTERFERENCE; UPREGULATION;

EID: 34547107098     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-059048     Document Type: Article

References (47)

1. de The H, Chelbi-Alix MK. APL, a model disease for cancer therapies? Oncogene. 2001;20:7136-7139.
2. Frankfurt O, Tallman MS. Strategies for the treatment of acute promyelocytic leukemia. J Natl Compr Canc Netw. 2006;4:37-50.
3. Sirulnik LA, Stone RM. Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol. 2005;3:391-397.
4. Mann KK, Shao W, Miller WH Jr. The biology of acute promyelocytic leukemia. Curr Oncol Rep. 2001;3:209-216.
5. Chambon P. Adecade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940-954.
6. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
7. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 2001;20:7186-7203.
8. Kastner P, Chan S. Function of RARalpha during the maturation of neutrophils. Oncogene. 2001;20:7178-7185.
9. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140-7145.
10. Tallman MS. Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol. 2004;41:27-32.
11. Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol. 2005;6:542-554.
12. Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 2001;20:7204-7215.
13. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia. 2003;17:1723-1730.
14. Kambhampati S, Verma A, Li Y, Parmar S, Sassano A, Platanias LC. Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma. 2004;45:2175-2185.
15. Liu TX, Zhang JW, Tao J, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood. 2000;96:1496-1504.
16. Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A. 1999;96:2907-2912.
17. Harris MN, Ozpolat B, Abdi F, et al. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 2004;104:1314-1323.
18. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
19. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci U S A. 2003;100:11712-11717.
20. Poeschla EM. Nonprimate lentiviral vectors. Curr Opin Mol Ther. 2003;5:529-540.
21. Luo HR, Huang YE, Chen JC, et al. Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell. 2003;114:559-572.
22. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene. 2001;20:7287-7291.
23. National Center for Biotechnology Information. NCBI RefSeq database. URL http: //www.ncbi.nlm.nih.gov/refseq/. Accessed July 1, 2005.
24. Gao M, Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell. 2005;19:581-593.
25. Baek KH. Cytokine-regulated protein degradation by the ubiquitination system. Curr Protein Pept Sci. 2006;7:171-177.
26. Saville MK, Sparks A, Xirodimas DP, et al. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem. 2004;279:42169-42181.
27. Obin M, Lee BY, Meinke G, et al. Ubiquitylation of the transducin betagamma subunit complex: regulation by phosducin. J Biol Chem. 2002;277:44566-44575.
28. Wang J, Barsky LW, Shum CH, et al. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem. 2002;277:43369-43376.
29. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002;99:2199-2206.
30. Otsuki T, Sakaguchi H, Hatayama T, Wu P, Takata A, Hyodoh F. Effects of all-trans retinoic acid (ATRA) on human myeloma cells. Leuk Lymphoma. 2003;44:1651-1656.
31. Maeda I, Ohta T, Koizumi H, Fukuda M. In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3. FEBS Lett. 2001;494:181-185.
32. Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacologic dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol. 2006;46:451-480.
33. Drager UC. Retinoic acid signaling in the functioning brain. Sci STKE. 2006;2006:pe10.
34. Clagett-Dame M, McNeill EM, Muley PD. Role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol. 2006;66:739-756.
35. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia. 2002;16:1896-1905.
36. Kawakami Y, Raya A, Raya RM, Rodriguez-Esteban C, Belmonte JC. Retinoic acid signalling links left-right asymmetric patterning and bilaterally symmetric somitogenesis in the zebrafish embryo. Nature. 2005;435:165-171.
37. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr. 2004;24:201-221.
38. Sun L, Chen ZJ. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol. 2004;16:119-126.
39. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003;15:164-171.
40. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene. 2004;23:2096-2106.
41. Ang XL, Harper JW. Interwoven ubiquitination oscillators and control of cell cycle transitions. Sci STKE. 2004;2004:pe31.
42. Yanagida M, Yamashita YM, Tatebe H, Ishii K, Kumada K, Nakaseko Y. Control of metaphase-anaphase progression by proteolysis: cyclosome function regulated by the protein kinase A pathway, ubiquitination and localization. Philos Trans R Soc Lond B Biol Sci. 1999;354:1559-1569; discussion 1569-1570.
43. Murray A. cyclin ubiquitination: the destructive end of mitosis. Cell. 1995;81:149-152.
44. Weissman AM. Regulating protein degradation by ubiquitination. Immunol Today. 1997;18:189-198.
45. Zhang XD, Matunis MJ. Ub in charge: regulating E2 enzyme nuclear import. Nat Cell Biol. 2005;7:12-14.
46. Banerjee D, Liefshitz A. Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res. 2001;21:3941-3947.
47. Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003;5:1-7.